Fatmaelzahraa Emad Abdelfattah

Dr. Fatmaelzahraa Emad Abdelfattah

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SESogol Attaripour Esfahani
Sogol Attaripour Esfahani
NANima Baba Ali
Nima Baba Ali
JFJuan M Farina
Juan M Farina
ISIsabel Grace Scalia
Isabel Grace Scalia
Milagros PereyraMilagros Pereyra
Milagros Pereyra
RAReza Arsanjani
Reza Arsanjani
Background: Pulmonary hypertension (PH) is a complex condition associated with significant morbidity and mortality. Traditional diagnostic and management approaches for PH often face limitations, leading to delays in diagnosis and potentially suboptimal treatment outcomes. Artificial intelligence (AI), encompassing machine learning (ML) and deep learning (DL) offers a transformative approach to PH care. Materials and Methods: We systematically searched PubMed, Scopus, and Web of Science for original studies on AI applications in PH, using predefined keywords. Out of more than 500 initial articles, 45 relevant studies were selected. Risk of bias was evaluated using PROBAST (Prediction model Risk of Bias Assessment Tool). Results: This review examines the potential applications of AI in PH, focusing on its role in enhancing diagnosis, disease classification, and prognostication. We discuss how AI-powered analysis of medical data can improve the accuracy and efficiency of detecting PH. Furthermore, we explore the potential of AI in risk stratification, leading to treatment optimization for PH. Conclusions: While acknowledging the existing challenges and limitations and the need for continued exploration and refinement of AI-driven tools, this review highlights the significant promise of AI in revolutionizing PH management to improve patient outcomes.

30 April 2024 in Obesity Surgery
Verified
Journal Article
Open access
PDF file
AAAhmed Abokhozima
Ahmed Abokhozima
mohamed Hossam zidanmohamed Hossam zidan
mohamed Hossam zidan
HAHashem Altabbaa
Hashem Altabbaa
AEAhmed Abo Elmagd
Ahmed Abo Elmagd
MAMohammed Alokl
Mohammed Alokl
ASAliaa Selim
Aliaa Selim
As bariatric surgeries (BS) increase, more incidental findings are liable to be discovered. Incidental gastric gastrointestinal stromal tumors (GISTs) during BS can be found in around 0.7% of the cases. In this article, we have performed a systematic review of the literature and added our data to those of the review to review a conceptual treatment strategy to both improve patient outcomes and decrease the risk of overall cancer. With the rise of new bariatric techniques, we have proposed a new classification to BS to enhance our description of the treatment strategy. Graphical Abstract

11 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ISIsabel Grace Scalia
Isabel Grace Scalia
GPGirish Pathangey
Girish Pathangey
MAMahmoud Abdelnabi
Mahmoud Abdelnabi
OIOmar H Ibrahim
Omar H Ibrahim
FAFatmaelzahraa Emad Abdelfattah
Fatmaelzahraa Emad Abdelfattah
CAChadi Ayoub
Chadi Ayoub
Cardiovascular diseases and cancer are the leading causes of morbidity and mortality in modern society. Expanding cancer therapies that have improved prognosis may also be associated with cardiotoxicity, and extended life span after survivorship is associated with the increasing prevalence of cardiovascular disease. As such, the field of cardio-oncology has been rapidly expanding, with an aim to identify cardiotoxicity and cardiac disease early in a patient who is receiving treatment for cancer or is in survivorship. Artificial intelligence is revolutionizing modern medicine with its ability to identify cardiac disease early. This article comprehensively reviews applications of artificial intelligence specifically applied to electrocardiograms, echocardiography, cardiac magnetic resonance imaging, and nuclear imaging to predict cardiac toxicity in the setting of cancer therapies, with a view to reduce early complications and cardiac side effects from cancer therapies such as chemotherapy, radiation therapy, or immunotherapy.

22 January 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
HSHesham Sheashaa
Hesham Sheashaa
HMHana Mousa
Hana Mousa
Mohammed Tiseer AbbasMohammed Tiseer Abbas
Mohammed Tiseer Abbas
JFJuan M Farina
Juan M Farina
KAKamal Awad
Kamal Awad
RAReza Arsanjani
Reza Arsanjani
Lipoprotein(a) [Lp(a)] is a well-established causal risk factor for cardiovascular diseases (CVDs), as reported by multiple Mendelian randomization studies and large epidemiological studies. When elevated Lp(a) is combined with other risk factors, most notably elevated low-density lipoprotein cholesterol (LDL-C), a synergistic atherogenic effect has been reported. However, the current literature is conflicting regarding how Lp(a) interacts in the context of controlled LDL-C levels (e.g., <70 mg/dL) and whether reducing LDL-C can modify the atherogenic effect of Lp(a). In some studies, elevated Lp(a) was still significantly associated with a higher risk of cardiovascular events, despite controlled levels of LDL-C. In contrast, multiple studies have reported attenuation of the cardiovascular risk mediated by elevated Lp(a) with lower LDL-C levels. Moreover, the relationship between Lp(a) and triglycerides, high-density lipoprotein, and very low-density lipoprotein remains unclear. In this literature review, we summarize and discuss the current evidence regarding the interactions between Lp(a) and other lipid molecules, how they contribute to the pathogenesis of CVD, and future perspectives, particularly in the current era where promising targeted Lp(a)-lowering therapies are under development.

9 January 2026 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
Mohammed Tiseer AbbasMohammed Tiseer Abbas
Mohammed Tiseer Abbas
JFJuan M. Farina
Juan M. Farina
OIOmar H. Ibrahim
Omar H. Ibrahim
SASherif Ahmed
Sherif Ahmed
NBNadera N. Bismee
Nadera N. Bismee
RAReza Arsanjani
Reza Arsanjani

Verified
Journal Article
Open access
PDF file
Abdelrahman HafezAbdelrahman Hafez
Abdelrahman Hafez
JFJuan M Farina
Juan M Farina
KAKamal Awad
Kamal Awad
Milagros PereyraMilagros Pereyra
Milagros Pereyra
ISIsabel Grace Scalia
Isabel Grace Scalia
RAReza Arsanjani
Reza Arsanjani
Coronary microvascular dysfunction (CMD) has emerged as a crucial contributor to cardiovascular morbidity and mortality, particularly in patients with ischemia and non-obstructive coronary arteries (INOCA). The condition arises from a complex interplay of structural and functional abnormalities within the small coronary vessels, driven by underlying molecular mechanisms including endothelial nitric oxide synthase (eNOS) uncoupling, oxidative stress, and chronic inflammation. Lipid metabolism plays a central role in this pathology, especially in the setting of elevated low-density lipoprotein cholesterol (LDL-C). Furthermore, the protective capacity of high-density lipoprotein (HDL) is increasingly understood to depend on its functionality rather than absolute levels, as it can become dysfunctional and pro-inflammatory in pathological states. Emerging evidence has identified lipoprotein(a) [Lp(a)] and triglyceride-rich lipoproteins as significant, independent contributors to microvascular injury. Comprehensive clinical assessment of microvascular dysfunction therefore requires integration of advanced lipid profiling, including apolipoprotein B (ApoB), [Lp(a)], and the triglyceride-glucose (TyG) index with invasive and non-invasive measures of coronary flow reserve to more precisely stratify risk. In this narrative review, we synthesize current observational, mechanistic, and early interventional data linking diverse lipid phenotypes to coronary microvascular dysfunction. We propose a concept of lipid-driven CMD endotypes, such as ApoB-/particle overload, dysfunctional HDL, Lp(a)-mediated risk, and metabolic/TyG-high states, and map these to a practical, mechanism-informed management framework. While intensive LDL-C lowering with high-intensity statins and combination therapy remains guideline-directed care for high-risk patients, evidence for dedicated microvascular benefit from newer lipid and cardiometabolic agents is still largely hypothesis-generating. A personalized approach that aligns lipid phenotyping, CMD endotyping, and existing guideline-based therapies may help refine risk assessment and inform future trials.